Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, and Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application (Immunology, Hematology, Infectious Disease, Hematology, and Others), By Techniques (Density Gradient Centrifugation, Leukapheresis, and Others), By Source (Human, Animals), By Region and Competition, 2020-2030F

Market Overview

Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

Key Market Drivers

Government-Funded Cell Therapy and Immunology Research

Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH) continues to back programs—such as immuno-oncology and vaccine research—that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)—a €2 billion public–private partnership co-funded by the European Commission—supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs’ indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.

Government Support for Biobanking and Systems Biology Platforms

Governments in both EU and China are investing in biobanking infrastructure and systems biology research, which is a vital component of PBMC-based investigations. The EU’s Horizon Europe program has increased science spending by nearly 50% for 2021–2027, boosting research infrastructure—such as biobanks and high-dimensional immunophenotyping centers—that utilize PBMC samples in personalized medicine projects. Furthermore, the EU’s EU4Health program, with a budget of €5.1 billion for 2021–2027, supports access to biological materials, data sharing, and standardized sample preparation protocols across member states—facilitating broader PBMC uptake in public health research. These public funding frameworks underpin long-term investments in PBMC repositories, standardized protocols, and cross-border research collaborations, making PBMCs central to government-endorsed research infrastructure.

Download Free Sample Report

Key Market Challenges

Regulatory and Quality Compliance Complexity

A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany’s Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR—violations can incur fines exceeding €20 million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.

High Cost of GMP-Compliant PBMC Production and Storage

Public health institutions and national regulators often require Good Manufacturing Practice (GMP) standards for PBMC production—especially for clinical and immuno-monitoring applications. Establishing and operating GMP-grade PBMC isolation and cryopreservation facilities demands expensive clean-room infrastructure, validated equipment, and ongoing regulatory audits. For example, Brazil’s regulatory overhaul in 2023 revealed that nearly one-third of public PBMC banks lacked validated cryopreservation protocols, forcing facility upgrades and record-retention standards mandated by ANVISA Resolution RDC 260/2018. Such compliance requirements—combined with the need for long-term storage, quality controls, and traceability—elevate production costs, limiting adoption in resource-limited health systems or smaller academic labs.

Key Market Trends

Expanding Role in Vaccine Development and Immuno-Monitoring

A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials—for diseases like COVID-19, malaria, tuberculosis—routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.

Growing Integration in Precision Medicine and Multi-Omics Research

PBMCs are increasingly integrated into systems biology and personalized medicine studies supported by government research frameworks. Horizon Europe’s emphasis on health systems transformation and the EU Cancer Mission leverage PBMC-derived single-cell and proteomic data for biomarker discovery and treatment stratification. National initiatives such as Europe–China collaborations under personalized medicine agendas use PBMC biobanks and harmonized protocols to link genotype–phenotype datasets across populations. This alignment with public-sector scientific priorities, especially for immunology-focused disease research—supports deeper multi-omics profiling and accelerates PBMC-centric innovation trajectories.

Segmental Insights

Product Insights

Based on Product, The Cryopreserved or Frozen Peripheral Blood Mononuclear Cells (PBMCs) segment holds the largest share in the global PBMCs market. This dominance is primarily due to the flexibility, stability, and scalability that cryopreserved PBMCs offer in biomedical and clinical research. These cells are pre-isolated, processed under standardized conditions, and stored in cryogenic facilities, enabling researchers to conduct experiments without immediate donor sample collection. Their availability in ready-to-use formats makes them a preferred choice for applications in immunological assays, vaccine testing, drug discovery, and disease modeling. Furthermore, cryopreserved PBMCs are integral to multi-center studies, where uniformity of biological samples is crucial to ensuring consistent results. Their use also minimizes the variability associated with freshly isolated cells, improving experimental reproducibility. These advantages have led to growing demand from pharmaceutical companies, contract research organizations, and academic institutions. Additionally, advancements in cryopreservation technologies, such as the use of optimized cryoprotectants and automated freezing systems, have enhanced cell viability and functionality post-thaw, further reinforcing their appeal. 

Download Free Sample Report

Regional Insights

Based on the region, North America accounts for the largest share of the global Peripheral Blood Mononuclear Cells (PBMCs) market, driven by its robust biomedical research infrastructure, high healthcare expenditure, and strong presence of leading pharmaceutical and biotechnology companies. The region benefits from advanced research facilities, well-established biobanks, and an increasing number of clinical trials focusing on immunotherapy, cell-based therapies, and vaccine development. Additionally, government funding from agencies like the National Institutes of Health (NIH) supports continued exploration of immune cells, which includes PBMCs. The favorable regulatory environment and higher adoption of cutting-edge biomedical technologies further cement North America’s leading position in the market.

Recent Developments

• In March 2025, Revelation Biosciences Inc. announced that its Gemini priming weakens the inflammatory response in human peripheral blood mononuclear cells (PBMCs) when exposed to clinically related inflammation promoter molecules. James Rolke, CEO of Revelation, said, “These exciting results further demonstrate the game-changing potential of Gemini to attenuate the inflammatory response to clinically relevant DAMPS (damage associated molecular patterns) and PAMPS (pathogen associated molecular pattern). We look forward to demonstrating the same protective effect in cells collected from CKD patients, which will be an excellent surrogate of future efficacy of Gemini in our target indications.”
• In July 2024, Scinai Immunotherapeutics Ltd., a biotechnology company concentrated on developing inflammation and immunology (I&I) biology products, declared promising results for in-vivo pre-clinical study of its novel anti IL-17A/F VHH antibody fragment ('NanoAb'), which is a local, pioneering, intralesional biological treatment for patients affected by mild to moderate plaque psoriasis. For the study, human peripheral blood mononuclear cells (PBMCs) were used for inducing psoriasis.
• In June 2024, QPS, a globally leading contract research organization (CRO), expanded its service capabilities with its new central laboratory facility for leukopak cell therapy and improved PBMC capabilities that will supplement the existing translational medicine, bioanalysis, and peripheral blood mononuclear cell (PBMC) laboratories further extending full-service global CRO offering of the current QPS for clinical trials and cell therapy development.

Key Market Players

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Corning Inc.
• Bio-Rad Laboratories Inc.
• ABCAM
• Biolegend Inc.
• ZEN-Bio Inc.
• DAPCEL, Inc.
• Creative Bioarray
• iXCells Biotechnologies USA, LLC

Report Scope:

In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peripheral Blood Mononuclear Cells Market, By Product:

o   Cryopreserved or Frozen PBMC

o   Cultured or Fresh PBMC

o   Peripheral Blood Mononuclear Cell Isolation & Viability Kits

• Peripheral Blood Mononuclear Cells Market, By Application:

o   Immunology

o   Infectious Disease

o   Hematology

o   Others

• Peripheral Blood Mononuclear Cells Market, By Technique:

o   Density Gradient Centrifugation Process

o   Leukapheresis

• Peripheral Blood Mononuclear Cells Market, By Source:

o   Human

o   Animals

• Peripheral Blood Mononuclear Cells Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.

Available Customizations:

Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Peripheral Blood Mononuclear Cells Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]